Drug Approval | September 04, 2021
Reliance Life Science gets go-ahead for Phase I clinical trial for Covid-19 vaccine
The trial will be conducted across eight sites in Maharashtra
The trial will be conducted across eight sites in Maharashtra
The trial will be conducted across 10 sites in India
The facility has the capacity to produce one crore doses per day
The company has to approach the DCGI for approval to commence the trials
This is the first of its kind vaccine for Covid 19 to get the go-ahead
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
A total quantum of more than 4.39 crore doses was also available for direct procurement by the states as well as private hospitals in the month of May 2021
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
Subscribe To Our Newsletter & Stay Updated
